Transcode Historical Balance Sheet

RNAZ Stock

USD 8.05 0.35 4.17%

Trend analysis of Transcode Therapeutics balance sheet accounts such as Total Current Assets of 6.6 M, Common Stock of 53.87, Total Assets of 8.1 M or Short Long Term Debt Total of 385.2 K provides information on Transcode Therapeutics' total assets, liabilities, and equity, which is the actual value of Transcode Therapeutics to its prevalent stockholders. By breaking down trends over time using Transcode Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Transcode Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Transcode Therapeutics is a good buy for the upcoming year.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Transcode Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

About Transcode Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Transcode Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Transcode Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Transcode Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Transcode currently owns. An asset can also be divided into two categories, current and non-current.

Transcode Therapeutics Balance Sheet Chart

At this time, Transcode Therapeutics' Other Liabilities is fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 4.1 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 2 M in 2025.

Total Current Liabilities Other Liab Total Current Assets Common Stock

Total Current Liabilities

Total Current Liabilities is an item on Transcode Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Transcode Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Current Assets

The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.

Most accounts from Transcode Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Transcode Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Transcode Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.At this time, Transcode Therapeutics' Other Liabilities is fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 4.1 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 2 M in 2025.

	2024	2025 (projected)
Other Liabilities	2.3M	2.4M
Total Current Liabilities	4.0M	2.0M

Other Liab Total Current Liabilities

Transcode Therapeutics balance sheet Correlations

	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Other Stockholder Equity	Total Current Assets	Common Stock	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Total Liab	Net Invested Capital	Capital Stock	Net Working Capital
Total Current Liabilities		0.84	0.54	-0.88	0.88	0.61	-0.15	0.64	-0.64	0.93	0.49	-0.52	0.97	0.5	0.75	0.36	-0.03	0.87	0.5	-0.36	0.66	-0.04	0.8	0.43	0.17	0.36
Other Liab	0.84		0.52	-0.83	0.87	0.63	-0.33	0.67	-0.31	0.91	0.47	-0.51	0.83	0.53	0.84	0.68	0.39	0.96	0.53	-0.55	0.71	0.01	0.94	0.44	0.05	0.4
Net Tangible Assets	0.54	0.52		-0.34	0.53	0.98	0.29	0.97	-0.57	0.58	0.99	-0.98	0.52	0.98	0.31	-0.08	-0.18	0.52	0.98	-0.16	0.22	-0.39	0.26	0.98	0.51	0.95
Retained Earnings	-0.88	-0.83	-0.34		-0.96	-0.39	0.55	-0.44	0.62	-0.94	-0.25	0.26	-0.83	-0.25	-0.95	-0.51	0.03	-0.78	-0.25	0.63	-0.92	0.26	-0.77	-0.18	0.27	-0.09
Other Stockholder Equity	0.88	0.87	0.53	-0.96		0.57	-0.47	0.62	-0.69	0.98	0.44	-0.45	0.83	0.44	0.95	0.43	-0.07	0.79	0.44	-0.71	0.9	-0.36	0.73	0.38	-0.16	0.29
Total Current Assets	0.61	0.63	0.98	-0.39	0.57		0.29	1.0	-0.5	0.64	0.98	-0.99	0.61	0.99	0.36	0.03	-0.03	0.63	0.99	-0.19	0.24	-0.23	0.41	0.97	0.56	0.95
Common Stock	-0.15	-0.33	0.29	0.55	-0.47	0.29		0.23	0.04	-0.32	0.38	-0.4	-0.03	0.38	-0.71	-0.64	-0.16	-0.24	0.38	0.6	-0.78	0.41	-0.32	0.41	0.91	0.46
Total Assets	0.64	0.67	0.97	-0.44	0.62	1.0	0.23		-0.52	0.69	0.96	-0.97	0.64	0.97	0.42	0.07	-0.02	0.66	0.97	-0.25	0.3	-0.25	0.45	0.95	0.51	0.93
Short Long Term Debt Total	-0.64	-0.31	-0.57	0.62	-0.69	-0.5	0.04	-0.52		-0.66	-0.5	0.46	-0.61	-0.41	-0.48	0.33	0.75	-0.25	-0.41	0.41	-0.54	0.57	-0.11	-0.43	-0.07	-0.32
Other Current Liab	0.93	0.91	0.58	-0.94	0.98	0.64	-0.32	0.69	-0.66		0.51	-0.52	0.91	0.51	0.89	0.41	-0.01	0.85	0.51	-0.63	0.82	-0.21	0.8	0.45	0.01	0.37
Total Stockholder Equity	0.49	0.47	0.99	-0.25	0.44	0.98	0.38	0.96	-0.5	0.51		-1.0	0.48	0.99	0.21	-0.12	-0.15	0.48	0.99	-0.06	0.11	-0.31	0.22	1.0	0.59	0.98
Net Debt	-0.52	-0.51	-0.98	0.26	-0.45	-0.99	-0.4	-0.97	0.46	-0.52	-1.0		-0.52	-1.0	-0.22	0.07	0.07	-0.53	-1.0	0.04	-0.1	0.23	-0.29	-0.99	-0.63	-0.98
Accounts Payable	0.97	0.83	0.52	-0.83	0.83	0.61	-0.03	0.64	-0.61	0.91	0.48	-0.52		0.5	0.67	0.28	-0.01	0.83	0.5	-0.37	0.56	0.1	0.81	0.43	0.3	0.36
Cash	0.5	0.53	0.98	-0.25	0.44	0.99	0.38	0.97	-0.41	0.51	0.99	-1.0	0.5		0.22	-0.02	-0.02	0.55	1.0	-0.05	0.1	-0.22	0.31	0.99	0.62	0.99
Non Current Assets Total	0.75	0.84	0.31	-0.95	0.95	0.36	-0.71	0.42	-0.48	0.89	0.21	-0.22	0.67	0.22		0.64	0.11	0.75	0.22	-0.77	0.98	-0.36	0.75	0.16	-0.43	0.08
Non Currrent Assets Other	0.36	0.68	-0.08	-0.51	0.43	0.03	-0.64	0.07	0.33	0.41	-0.12	0.07	0.28	-0.02	0.64		0.78	0.7	-0.02	-0.33	0.54	0.15	0.77	-0.12	-0.41	-0.11
Other Assets	-0.03	0.39	-0.18	0.03	-0.07	-0.03	-0.16	-0.02	0.75	-0.01	-0.15	0.07	-0.01	-0.02	0.11	0.78		0.42	-0.02	0.04	-0.05	0.57	0.55	-0.1	-0.01	-0.02
Long Term Debt	0.87	0.96	0.52	-0.78	0.79	0.63	-0.24	0.66	-0.25	0.85	0.48	-0.53	0.83	0.55	0.75	0.7	0.42		0.55	-0.35	0.6	0.08	0.94	0.46	0.13	0.43
Cash And Short Term Investments	0.5	0.53	0.98	-0.25	0.44	0.99	0.38	0.97	-0.41	0.51	0.99	-1.0	0.5	1.0	0.22	-0.02	-0.02	0.55		-0.05	0.1	-0.22	0.31	0.99	0.62	0.99
Common Stock Total Equity	-0.36	-0.55	-0.16	0.63	-0.71	-0.19	0.6	-0.25	0.41	-0.63	-0.06	0.04	-0.37	-0.05	-0.77	-0.33	0.04	-0.35	-0.05		-0.8	0.38	-0.43	-0.02	0.45	0.05
Common Stock Shares Outstanding	0.66	0.71	0.22	-0.92	0.9	0.24	-0.78	0.3	-0.54	0.82	0.11	-0.1	0.56	0.1	0.98	0.54	-0.05	0.6	0.1	-0.8		-0.5	0.6	0.05	-0.57	-0.04
Non Current Liabilities Total	-0.04	0.01	-0.39	0.26	-0.36	-0.23	0.41	-0.25	0.57	-0.21	-0.31	0.23	0.1	-0.22	-0.36	0.15	0.57	0.08	-0.22	0.38	-0.5		0.29	-0.28	0.46	-0.21
Total Liab	0.8	0.94	0.26	-0.77	0.73	0.41	-0.32	0.45	-0.11	0.8	0.22	-0.29	0.81	0.31	0.75	0.77	0.55	0.94	0.31	-0.43	0.6	0.29		0.2	0.04	0.18
Net Invested Capital	0.43	0.44	0.98	-0.18	0.38	0.97	0.41	0.95	-0.43	0.45	1.0	-0.99	0.43	0.99	0.16	-0.12	-0.1	0.46	0.99	-0.02	0.05	-0.28	0.2		0.62	0.99
Capital Stock	0.17	0.05	0.51	0.27	-0.16	0.56	0.91	0.51	-0.07	0.01	0.59	-0.63	0.3	0.62	-0.43	-0.41	-0.01	0.13	0.62	0.45	-0.57	0.46	0.04	0.62		0.66
Net Working Capital	0.36	0.4	0.95	-0.09	0.29	0.95	0.46	0.93	-0.32	0.37	0.98	-0.98	0.36	0.99	0.08	-0.11	-0.02	0.43	0.99	0.05	-0.04	-0.21	0.18	0.99	0.66

Click cells to compare fundamentals

Transcode Therapeutics Account Relationship Matchups

Transcode Therapeutics balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Current Liabilities	404.9K	2.5M	4.3M	3.5M	4.0M	2.0M
Net Tangible Assets	(1.1M)	(3.4M)	20.4M	3.2M	3.7M	4.1M
Retained Earnings	(3.5M)	(10.3M)	(27.9M)	(46.4M)	(41.8M)	(39.7M)
Other Stockholder Equity	65.9K	30.7M	31.1M	48.1M	55.3M	58.0M
Total Current Assets	831.2K	22.7M	7.4M	4.5M	5.1M	6.6M
Total Assets	1.1M	22.9M	7.6M	5.2M	5.9M	8.1M
Total Stockholder Equity	(3.4M)	20.4M	3.2M	1.6M	1.9M	1.8M
Net Debt	1.3M	(20.8M)	(5.0M)	(2.3M)	(2.1M)	(2.2M)
Accounts Payable	369.2K	2.0M	4.3M	2.3M	2.7M	2.0M
Cash	828.0K	20.8M	5.0M	2.8M	3.2M	3.0M
Non Current Assets Total	224.2K	206.3K	208.6K	714.3K	821.4K	862.5K
Cash And Short Term Investments	828.0K	20.8M	5.0M	2.8M	3.2M	3.0M
Common Stock Shares Outstanding	8.0K	16.1K	16.2K	179.0K	205.9K	216.2K
Liabilities And Stockholders Equity	1.1M	22.9M	7.6M	5.2M	5.9M	8.1M
Non Current Liabilities Total	4.1M	30.5K	4.3M	38.3K	34.5K	32.7K
Total Liab	4.5M	2.5M	4.3M	3.5M	4.1M	3.6M
Net Invested Capital	(1.3M)	20.4M	3.2M	1.6M	1.9M	1.8M
Net Working Capital	426.4K	20.2M	3.0M	964.8K	1.1M	1.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Transcode Historical Balance Sheet

About Transcode Balance Sheet Analysis

Transcode Therapeutics Balance Sheet Chart

Total Current Liabilities

Total Current Assets

Transcode Therapeutics balance sheet Correlations

Transcode Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Transcode Therapeutics balance sheet Accounts

Also Currently Popular

Additional Tools for Transcode Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Assets	+ 1.0	Total Current Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.99	Net Tangible Assets
Cash	+ 0.99	Total Current Assets
Cash And Short Term Investments	+ 0.99	Total Current Assets

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 1.0	Total Stockholder Equity
Net Invested Capital	- 0.99	Net Debt
Net Debt	- 0.99	Total Current Assets
Net Working Capital	- 0.98	Net Debt